134 related articles for article (PubMed ID: 27977332)
1. Clinical impact of the CYP3A5 6986A>G allelic variant on kidney transplantation outcomes.
Flahault A; Anglicheau D; Loriot MA; Thervet E; Pallet N
Pharmacogenomics; 2017 Jan; 18(2):165-173. PubMed ID: 27977332
[TBL] [Abstract][Full Text] [Related]
2. Influence of CYP3A5 Genetic Polymorphism on Long-Term Renal Function in Chinese Kidney Transplant Recipients Using Limited Sampling Strategy and Abbreviated Area Under the Curve for Tacrolimus Monitoring.
Cheung CY; Chan KM; Wong YT; Chak WL; Bekers O; van Hooff JP
Prog Transplant; 2020 Sep; 30(3):249-253. PubMed ID: 32552577
[TBL] [Abstract][Full Text] [Related]
3. Effect of CYP3A5 polymorphism on the pharmacokinetics of tacrolimus and acute rejection in renal transplant recipients: experience at a single centre.
Cheng Y; Li H; Meng Y; Liu H; Yang L; Xu T; Yu J; Zhao N; Liu Y
Int J Clin Pract Suppl; 2015 May; (183):16-22. PubMed ID: 26177012
[TBL] [Abstract][Full Text] [Related]
4. Influence of CYP3A5 genetic polymorphism on tacrolimus daily dose requirements and acute rejection in renal graft recipients.
Quteineh L; Verstuyft C; Furlan V; Durrbach A; Letierce A; Ferlicot S; Taburet AM; Charpentier B; Becquemont L
Basic Clin Pharmacol Toxicol; 2008 Dec; 103(6):546-52. PubMed ID: 19067682
[TBL] [Abstract][Full Text] [Related]
5. CYP3A5 and ABCB1 polymorphisms in donor and recipient: impact on Tacrolimus dose requirements and clinical outcome after renal transplantation.
Glowacki F; Lionet A; Buob D; Labalette M; Allorge D; Provôt F; Hazzan M; Noël C; Broly F; Cauffiez C
Nephrol Dial Transplant; 2011 Sep; 26(9):3046-50. PubMed ID: 21677300
[TBL] [Abstract][Full Text] [Related]
6. Impact of tacrolimus intraindividual variability and CYP3A5 genetic polymorphism on acute rejection in kidney transplantation.
Ro H; Min SI; Yang J; Moon KC; Kim YS; Kim SJ; Ahn C; Ha J
Ther Drug Monit; 2012 Dec; 34(6):680-5. PubMed ID: 23149441
[TBL] [Abstract][Full Text] [Related]
7. CYP3A5 genotype is not associated with a higher risk of acute rejection in tacrolimus-treated renal transplant recipients.
Hesselink DA; van Schaik RH; van Agteren M; de Fijter JW; Hartmann A; Zeier M; Budde K; Kuypers DR; Pisarski P; Le Meur Y; Mamelok RD; van Gelder T
Pharmacogenet Genomics; 2008 Apr; 18(4):339-48. PubMed ID: 18334918
[TBL] [Abstract][Full Text] [Related]
8. Effects of combinational CYP3A5 6986A>G polymorphism in graft liver and native intestine on the pharmacokinetics of tacrolimus in liver transplant patients: a meta-analysis.
Buendia JA; Bramuglia G; Staatz CE
Ther Drug Monit; 2014 Aug; 36(4):442-7. PubMed ID: 24378577
[TBL] [Abstract][Full Text] [Related]
9. Effect of CYP3A5*3 on kidney transplant recipients treated with tacrolimus: a systematic review and meta-analysis of observational studies.
Rojas L; Neumann I; Herrero MJ; Bosó V; Reig J; Poveda JL; Megías J; Bea S; Aliño SF
Pharmacogenomics J; 2015 Feb; 15(1):38-48. PubMed ID: 25201288
[TBL] [Abstract][Full Text] [Related]
10. A Lack of Significant Effect of POR*28 Allelic Variant on Tacrolimus Exposure in Kidney Transplant Recipients.
Jannot AS; Vuillemin X; Etienne I; Buchler M; Hurault de Ligny B; Choukroun G; Colosio C; Thierry A; Vigneau C; Moulin B; Rerolle JP; Heng AE; Subra JF; Legendre C; Beaune P; Loriot MA; Thervet E; Pallet N
Ther Drug Monit; 2016 Apr; 38(2):223-9. PubMed ID: 26829596
[TBL] [Abstract][Full Text] [Related]
11. Tacrolimus trough and dose intra-patient variability and CYP3A5 genotype: Effects on acute rejection and graft failure in European American and African American kidney transplant recipients.
Seibert SR; Schladt DP; Wu B; Guan W; Dorr C; Remmel RP; Matas AJ; Mannon RB; Israni AK; Oetting WS; Jacobson PA
Clin Transplant; 2018 Dec; 32(12):e13424. PubMed ID: 30318646
[TBL] [Abstract][Full Text] [Related]
12. Prograf produces more benefits for CYP3A5 low expression patients in early stage after kidney transplantation.
Fan B; Qiu K; Jiang Y; Hu X; Yin H; Wang W; Ren L; Liu H; Wang W; Zhang X
Biomed Pharmacother; 2017 Apr; 88():738-744. PubMed ID: 28157649
[TBL] [Abstract][Full Text] [Related]
13. Impact of CYP3A5 genomic variances on clinical outcomes among African American kidney transplant recipients.
Asempa TE; Rebellato LM; Hudson S; Briley K; Maldonado AQ
Clin Transplant; 2018 Jan; 32(1):. PubMed ID: 29161757
[TBL] [Abstract][Full Text] [Related]
14. CYP3A5 gene polymorphisms and their impact on dosage and trough concentration of tacrolimus among kidney transplant patients: a systematic review and meta-analysis.
Khan AR; Raza A; Firasat S; Abid A
Pharmacogenomics J; 2020 Aug; 20(4):553-562. PubMed ID: 31902947
[TBL] [Abstract][Full Text] [Related]
15. CYP3A5 genotype affects time to therapeutic tacrolimus level in pediatric kidney transplant recipients.
Yanik MV; Seifert ME; Locke JE; Hauptfeld-Dolejsek V; Crowley MR; Cutter GR; Mannon RB; Feig DI; Limdi NA
Pediatr Transplant; 2019 Aug; 23(5):e13494. PubMed ID: 31124575
[TBL] [Abstract][Full Text] [Related]
16. Liver Transplant Patient Carriers of Polymorphism Cyp3a5*1 Donors May Need More Doses of Tacrolimus From the First Month After Transplantation.
Argudo A; González de Aledo JM; Alía P; Ramírez P; Serrano T; Fabregat J; Castellote J
Transplant Proc; 2015 Oct; 47(8):2388-92. PubMed ID: 26518936
[TBL] [Abstract][Full Text] [Related]
17. Polymorphism of the CYP3A5 gene and its effect on tacrolimus blood level.
Nair SS; Sarasamma S; Gracious N; George J; Anish TS; Radhakrishnan R
Exp Clin Transplant; 2015 Apr; 13 Suppl 1():197-200. PubMed ID: 25894154
[TBL] [Abstract][Full Text] [Related]
18. The effect of CYP3A5 6986A>G and ABCB1 3435C>T on tacrolimus dose-adjusted trough levels and acute rejection rates in renal transplant patients: a systematic review and meta-analysis.
Terrazzino S; Quaglia M; Stratta P; Canonico PL; Genazzani AA
Pharmacogenet Genomics; 2012 Aug; 22(8):642-5. PubMed ID: 22786571
[TBL] [Abstract][Full Text] [Related]
19. Genomewide Association Study of Tacrolimus Concentrations in African American Kidney Transplant Recipients Identifies Multiple CYP3A5 Alleles.
Oetting WS; Schladt DP; Guan W; Miller MB; Remmel RP; Dorr C; Sanghavi K; Mannon RB; Herrera B; Matas AJ; Salomon DR; Kwok PY; Keating BJ; Israni AK; Jacobson PA;
Am J Transplant; 2016 Feb; 16(2):574-82. PubMed ID: 26485092
[TBL] [Abstract][Full Text] [Related]
20. Donor CYP3A5 Expression Decreases Renal Transplantation Outcomes in White Renal Transplant Recipients.
Warzyszyńska K; Zawistowski M; Karpeta E; Jałbrzykowska A; Kosieradzki M
Ann Transplant; 2022 Jul; 27():e936276. PubMed ID: 35879888
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
